Hikma: Biolinq raises $100m to support US launch of intradermal glucose sensor
Biolinq has secured $100m in Series C funds to support the regulatory approval process in the US to launch its intradermal glucose sensor. The post Biolinq raises $100m to support US launch of intradermal glucose sensor appeared first on Medical Device Network.
Read full article »
Hikma is an England-based multinational pharmaceutical company that develops, manufactures and markets generic and specialty medicines for the healthcare sector.
Read more